Preimplantation genetic diagnosis as a source of human embryonic stem cells for disease research and drug discovery
Article first published online: 12 DEC 2008
© 2008 The Authors Journal compilation © RCOG 2008 BJOG An International Journal of Obstetrics and Gynaecology
BJOG: An International Journal of Obstetrics & Gynaecology
Special Issue: Emerging Technologies in Obstetrics and Gynaecology
Volume 116, Issue 2, pages 158–165, January 2009
How to Cite
Stephenson, E., Mason, C. and Braude, P. (2009), Preimplantation genetic diagnosis as a source of human embryonic stem cells for disease research and drug discovery. BJOG: An International Journal of Obstetrics & Gynaecology, 116: 158–165. doi: 10.1111/j.1471-0528.2008.02009.x
- Issue published online: 12 DEC 2008
- Article first published online: 12 DEC 2008
- Accepted 25 September 2008.
- disease modelling;
- drug discovery;
- embryonic stem cells;
- preimplantation genetic diagnosis
Embryos surplus to therapeutic requirements following preimplantation genetic diagnosis can be used to derive human embryonic stem cell (hESC) lines carrying mutations significant to human disease. These cells provide a powerful in vitro tool for modelling disease progression in a number of cell types as well as having the potential to revolutionise drug discovery. Robust and reproducible directed differentiation protocols are needed to maximise the potential of these cells. In this review, we explore the current use of hESC and induced pluripotent stem cells in disease-specific research and discuss the use of stem cell technology in drug discovery and toxicity testing.